Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07195032

Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Children's Mercy Hospital Kansas City · Academic / Other
Sex
All
Age
1 Year – 17 Years
Healthy volunteers
Not accepted

Summary

The study is an interventional, non-randomized assessment of safety and efficacy of live Measles, Mumps and Rubella (MMR) vaccine in subjects aged 12-months to 17 years who have undergone heart transplantation. Subjects who provide permission/assent will receive the commercial MMR vaccine according to product indication and labeling.

Conditions

Interventions

TypeNameDescription
DRUGCommercial measles, mumps, and rubella (MMR) vaccineParticipants will receive the commercial MMR vaccine if they are deemed eligible for the study.

Timeline

Start date
2025-09-11
Primary completion
2027-09-11
Completion
2027-09-11
First posted
2025-09-26
Last updated
2025-09-26

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT07195032. Inclusion in this directory is not an endorsement.

Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients (NCT07195032) · Clinical Trials Directory